v3.25.2
Note 7 - Segment Information
 6 Months Ended
Jun. 30, 2025
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 7 – Segment Information

 

We manage our business activities on a consolidated basis and operate as a single operating segment dedicated to developing and marketing products for chronic wound care that harness the regenerative capacity of the human body to trigger natural healing. We derive our revenue from product sales of the Aurix product line. The accounting policies of the segment are the same as those described in Note 2 – Liquidity and Summary of Significant Accounting Policies.

 

Our CODM is Nuo's Chief Executive and Financial Officer, David E. Jorden. The CODM uses net loss, as reported in our consolidated statements of operations, in evaluating the performance of the segment and determining how to allocate our resources of as a whole. The CODM does not review assets in evaluating the results of the segment, and therefore, such information is not presented.

 

The following table presents the operating results of the segment:

 

 

   

Three Months

Ended June 30,

    

Three Months

Ended June 30,

    

Six Months

Ended June 30,

    

Six Months

Ended June 30,

  
    2025     2024    

2025

    

2024

  

Total revenues

     700,202       364,773     $ 1,184,583     $ 599,350  

Less significant segment expenses:

                                

Cost of sales (excluding provision for inventory obsolescence and applicable depreciation expense)

     140,807       65,335       241,499       115,926  

Total compensation and benefit costs (including third party commission expense)

     645,902       510,544       1,208,809       994,536  

Provisions for credit losses and inventory obsolescence

     -       -       21,644       17,500  

All other operating expenses (excluding depreciation and credit loss provision) (a)

     501,604       284,141       993,948       669,032  

Other segment items:

                                

Depreciation, amortization of right of use assets, and stock-based compensation

     63,911       46,735       115,852       53,584  

Interest expense (income), net

     (1,153 )     (541 )     442       (1,006 )

Other expense (income), net

     (1,180 )     (1,350 )     (1,794 )     (1,350 )

Consolidated net loss

     (649,689 )     (540,091 )   $ (1,395,817 )   $ (1,248,872 )

 

 

(a) All other operating expenses included in consolidated net loss includes professional fees, lease expenses, insurance costs, travel and entertainment expenses, and all other selling, general and administrative expenses.